Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon

Keizo Kanasaki¹,²*, Emi Kawakita¹ and Daisuke Koya¹,²*

¹ Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Japan, ² Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute, Kanazawa Medical University, Uchinada, Japan

The biology of autophagy in health and disease conditions has been intensively analyzed for decades. Several potential interventions can induce autophagy in preclinical research; however, none of these interventions are ready for translation to clinical practice yet. The topic of the current review is the molecular regulation of autophagy by glucagon, glucagon-like peptide (GLP)-1 and the GLP-1-degrading enzyme dipeptidyl peptidase-4 (DPP-4). Glucagon is a well-known polypeptide that induces autophagy. In contrast, GLP-1 has been shown to inhibit glucagon secretion; GLP-1 also has been related to the induction of autophagy in a GLP-1–dependent manner, but other diverse effects could be relevant. Here, we analyze the distinct molecular regulation of autophagy by glucagon, GLP-1, and DPP-4 inhibitors. Additionally, the potential contribution to autophagy by glucagon and GLP-1 after bariatric surgery is discussed.

Keywords: autophagy, incretin, GLP-1, DPP-4, glucagon

INTRODUCTION

Recent advances with incretin-based drugs have opened new avenues in the management of diabetes. In the clinic, we can prescribe two types of incretin-based drugs: glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 is produced from intestinal L-cells by proteolytical processing from proglucagon (ProG) and immediately degraded by DPP-4; its half-life is approximately 2 min. GLP-1RAs have been developed to avoid DPP-4-mediated cleavage of GLP-1 by introducing a mutation in the amino acid residue that DPP-4 targets. Exenatide (Exendin-4), a 39-amino-acid polypeptide isolated from the venom of the Gila monster lizard with 50% homology to human GLP-1, has been used in the clinic. Alternatively, to extend the half-life of endogenous GLP-1, DPP-4 inhibitors are prescribed. Recent clinical trials (Marso et al., 2016, 2017; Rosenstock et al., 2019) investigating the safety and efficacy of incretin-based drugs have provided diverse interpretations and provocative intellectual curiosities regarding the biology of incretin hormones and incretin-based drugs, specifically focusing on pleiotropic effects.

Autophagy, the cellular mechanism that promotes cell survival during nutrient depletion, may also be relevant under basal or nutrient excess conditions. This cellular process is specified by the formation of autophagosomes, by which cytosolic components are captured and fused with lysosomes to promote the degradation and/or recycling of its contents. The autophagic

The biology of autophagy in health and disease conditions has been intensively analyzed for decades. Several potential interventions can induce autophagy in preclinical research; however, none of these interventions are ready for translation to clinical practice yet. The topic of the current review is the molecular regulation of autophagy by glucagon, glucagon-like peptide (GLP)-1 and the GLP-1-degrading enzyme dipeptidyl peptidase-4 (DPP-4). Glucagon is a well-known polypeptide that induces autophagy. In contrast, GLP-1 has been shown to inhibit glucagon secretion; GLP-1 also has been related to the induction of autophagy in a GLP-1–dependent manner, but other diverse effects could be relevant. Here, we analyze the distinct molecular regulation of autophagy by glucagon, GLP-1, and DPP-4 inhibitors. Additionally, the potential contribution to autophagy by glucagon and GLP-1 after bariatric surgery is discussed.

Keywords: autophagy, incretin, GLP-1, DPP-4, glucagon

INTRODUCTION

Recent advances with incretin-based drugs have opened new avenues in the management of diabetes. In the clinic, we can prescribe two types of incretin-based drugs: glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 is produced from intestinal L-cells by proteolytical processing from proglucagon (ProG) and immediately degraded by DPP-4; its half-life is approximately 2 min. GLP-1RAs have been developed to avoid DPP-4-mediated cleavage of GLP-1 by introducing a mutation in the amino acid residue that DPP-4 targets. Exenatide (Exendin-4), a 39-amino-acid polypeptide isolated from the venom of the Gila monster lizard with 50% homology to human GLP-1, has been used in the clinic. Alternatively, to extend the half-life of endogenous GLP-1, DPP-4 inhibitors are prescribed. Recent clinical trials (Marso et al., 2016, 2017; Rosenstock et al., 2019) investigating the safety and efficacy of incretin-based drugs have provided diverse interpretations and provocative intellectual curiosities regarding the biology of incretin hormones and incretin-based drugs, specifically focusing on pleiotropic effects.

Autophagy, the cellular mechanism that promotes cell survival during nutrient depletion, may also be relevant under basal or nutrient excess conditions. This cellular process is specified by the formation of autophagosomes, by which cytosolic components are captured and fused with lysosomes to promote the degradation and/or recycling of its contents. The autophagic
process consists of four stages: initiation, nucleation, elongation, and fusion/degradation (Codogno et al., 2011). During nutrient depletion, autophagy can provide essential components for energy production and biosynthesis. However, it also acts in a similar manner by recycling damaged organelles, unnecessary proteins, and foreign substances for the quality maintenance of these intracellular components (Ueno and Komatsu, 2017). In circumstances of nutrient excess, autophagy plays important roles in eliminating unfolded proteins and toxic aggregates and facilitating endoplasmic reticulum (ER) homeostasis. The detailed mechanisms and biology of autophagy are summarized in subsequent sections of this issue.

Autophagy defects in certain diseases have been the subject of extensive research. In addition, liver autophagy defects have been shown to occur with several metabolic diseases, such as obesity, steatosis, and type 2 diabetes (Ueno and Komatsu, 2017). Early work in liver research indicates a link in the regulation between gastrointestinal hormones and liver autophagy (Ueno and Komatsu, 2017). Interestingly, incretin hormones and DPP-4 inhibitors have been associated with the amelioration of steatosis (Rowlands et al., 2018; Zheng et al., 2018). These drugs have been shown to induce autophagy in various cell types (Murase et al., 2015; Rowlands et al., 2018; Zheng et al., 2018).

In this review, we investigated the potential involvement of autophagy induction by GLP-1 and incretin-based drugs. In addition, we focused on glucagon, a known polypeptide that regulates glucose levels and a classic molecule that induces autophagy.

GLUCAGON AND GLP-1 SYNTHESIS FROM PROGLUCAGON

GLP-1 is produced from proteolytic cleavage of the precursor polypeptide pProG (Muller et al., 2017). The pProG gene (Gcg) is expressed in a specific population of enteroendocrine cells (L-cells) in the intestinal mucosa, islet cells in the pancreas, and some neurons within the nucleus of the solitary tract (NTS) (Han et al., 1986; Jin et al., 1988). Regulation of the Gcg transcription process is not completely known and distinct pattern of mRNA expression has been reported in intestinal endocrine cells and in pancreatic islet α-cells (Jin, 2008; Yi et al., 2008; Chiang et al., 2012; Muller et al., 2017). In addition to such unique transcriptional control in each cell type, posttranslational processing of prohormone plays an important role in the major cell types producing ProG peptides. In addition to glucagon and GLP-1, glucagon-like peptide-2 (GLP-2), oxyntomodulin, glicentin, glicentin-related pancreatic polypeptide (GRPP), and major proglucagon fragment (MPGF) are synthesized from ProG; however, the specific biological function of some of these fragments has not been identified (Figure 1). Such posttranslational regulation of these ProG peptides in their respective cell types relies on tissue-specific posttranslational modification by prohormone convertases (PCs). In intestinal L-cells and neurons of the NTS, a predominance of PC1/3 expression, GLP-1, oxyntomodulin, and GLP-2 are seen as physiologically relevant (Tucker et al., 1996; Larsen et al., 1997; Vrang et al., 2007); in pancreatic α-cells, high PC2 levels are responsible for the predominant glucagon synthesis (Figure 1).
PC2 is also expressed in the brain but does not colocalize with Ggc. Additionally, PC1/3 is expressed in α-cells but at lower levels than PC2, and the ratio of GLP-1 to glucagon expressed in islet cells has been shown to be increased during the progression of diabetes (O’Malley et al., 2014). Ggc expression and ProG levels are relatively lower in the proximal gut and higher in the distal part, with the highest expression in the colon (Bryant and Bloom, 1979).

GLUCAGON AND AUTOPHAGY

The association between autophagy and glucagon was reported approximately 50 years ago. In 1955, Christian de Duve reported on acid phosphatase-positive sac-like particles in rat liver cytoplasm (De Duve et al., 1955). Electron microscopy analysis revealed that such particles are surrounded by a lipoprotein membrane (Novikoff et al., 1956) and later showed acid hydrolases in these organelles, which were subsequently named lysosomes.

Secreted glucagon is recognized by the glucagon receptor (α G protein-coupled receptor) on the hepatocyte, subsequently adenyl cyclase-mediated productions of the second messenger cAMP was stimulated. Rise in the intracellular level of cAMP activates protein kinase A (PKA) and inhibits salt-inducible kinases (SIK). PKA phosphorylates Ser133 of cyclic AMP-responsive element-binding protein (CREB) and SIK dephosphorylates Ser171 of CREB-regulated transcription co-activator (CRTC). Ser133-phosphorylated CREB together with CRTC upregulates CREB target genes such as the gluconeogenesis-related genes PGC1α, nuclear receptor subfamily 4 group A member 1 (NR4A1) and TFEB which regulates gene expressions of autophagy proteins (Ueno and Komatsu, 2017).

In 1962, seminal work by Ashford and Porter (1962) found that glucagon administration increased the autophagy in liver. Subsequently, the role of glucagon in hepatocyte autophagy induction was confirmed in vivo by studies in rats (Arstila and Trump, 1968; Guder et al., 1970; Deter, 1971). Such effects of glucagon on the autophagy are likely tissue specific manner (Mortimore and Poso, 1987). Glucagon could induce autophagy by increasing the size and number of autophagic vacuoles (Guder et al., 1970; Deter, 1971; Shelburne et al., 1973); in addition, glucagon enhanced the fragility of hepatic lysosomes both mechanically and osmotically and altered sedimentation properties (Deter and De Duve, 1967). Such effects of glucagon on the hepatic lysosome appeared 30 min after intraperitoneal administration of glucagon, peaked for 15–30 min, and disappeared after approximately 4 h (Deter and De Duve, 1967).

The number of hepatic lysosomes increased under conditions associated with an increase in endogenous glucagon levels, such as starvation (Guder et al., 1970), hypoglycemia induced by phlorizin (Becker and CornwallJr., 1971), or type 1 diabetes (Amherdt et al., 1974). Supporting these findings, a significant correlation between the parameters of hepatic lysosomal volume density and plasma glucagon was observed in rats with type 1 diabetes induced by streptozotocin, and insulin intervention in these rats led to suppression of glucose and glucagon levels (Amherdt et al., 1974). In addition, pancreatic transplantation normalized liver autophagy levels in rats with streptozotocin-induced diabetes by restoring insulin and glucagon levels (Brekke et al., 1983). Glucagon is relevant to glucagon-mediated glycogenolysis; glycogen granules are selectively enveloped by autophagosomes for catabolism into glucose. This special type of autophagy is termed glycoaphagy.

GLP-1-RELATED AUTOPHAGY

GLP-1RA has been shown to suppress glucagon levels (Mentis et al., 2011). Even though tissue diversity effects of glucagon on the autophagy induction, the liver is the established target organ for glucagon-induced autophagy; therefore, from this point of view, GLP-1 signaling could be relevant to inhibiting autophagy induction in liver. Recently, however, GLP-1 has also been implicated in the induction of autophagy in the liver (He et al., 2016) and in β cells (Zummo et al., 2017; Arden, 2018) as well.

GLP-1 can protect β cells from insults induced by chronic exposure to excess nutrients via induction of autophagosomal-lysosomal fusion (Zummo et al., 2017; Arden, 2018). Exendin-4, an agonistic polypeptide for human GLP-1R derived from the venom of the Gila monster lizard, has also been shown to enhance lysosomal function in β-cells, improve autophagosome clearance and protect against islet injury in a rat model of tacrolimus-induced diabetes (Lim et al., 2016). Indeed, in this study, β cells from rats administered Exendin-4 showed a reduction in the number of autophagosomes (Lim et al., 2016).

Therefore, in certain environments, contrary to the hypothesis of the antiglucagon and antiautophagic signaling effects of GLP-1, GLP-1 receptor signaling could be relevant to the accelerated effects on autophagosomal-lysosomal fusion and the positive mediation of autophagic flux. However, the role of GLP-1 in β-cell autophagy is complex and likely dependent on stress conditions. In a rat model fed with high levels of fructose, GLP-1 analog intervention induced notable inhibition of β cell autophagy and enhanced β cell mass and function (Maïtéguì et al., 2017). The detailed molecular regulation of the autophagy system in β cells via GLP-1 receptor signaling requires further investigation.

The liver is the potential target organ for GLP-1-induced autophagy (He et al., 2016). Among the organs, the level of GLP-1 in the liver is highest because of transport through the hepatic portal vein from the gut. Intervention of GLP-1 or its analogs could ameliorate several aspects of liver injury (D’Alesio et al., 2004; Cantini et al., 2016) and influence hepatic gluconeogenesis, glycogen synthesis, and glycolysis (Figure 2). For the effects of GLP-1, its receptor GLP-1R is essential; the presence of GLP-1R is controversial in hepatocytes and the focus of intense discussion. Protein expression of GLP-1R has been reported in transformed human hepatocyte cell lines, Hep-G2, HuH7, and primary human hepatocytes (Gupta et al., 2010). Even though there is confirmation of GLP-1R expression on hepatocytes, research has suggested that some effects of GLP-1 are indeed GLP-1R-independent events (Bullock et al., 1996;
FIGURE 2 | GLP-1 receptor signaling and induction of autophagy. (A) GLP-1 receptor signaling activated PKA signaling, and subsequent activation of Akt and AMPK induced the proautophagic molecule Beclin-1. (B) GLP-1 receptor signaling is associated with NFR2 activation and the subsequent induction of oxidative stress-responsive genes. Even though detailed mechanisms have not yet been elucidated, GLP-1 signaling could potentially induce the interaction between SQSTM1 and KEAP1, resulting in the suppression of KEAP1-driven ubiquitination of NRF2; phosphorylated SQSTM1 and KEAP1 complexes are selectively degraded by autophagy. The involvement of sestrin2 associated with GLP-1 receptor signaling has not yet been analyzed. SESN2, sestrin2.

Flock et al., 2007; Aviv et al., 2009; Tomas et al., 2010). An alternative possible explanation could be based on the GLP-1 degradation products, such as GLP-1 9–36, GLP-1 28–36, or GLP-1 32–36. Studies have indicated that both GLP-1 28–36 and GLP-1 32–36 are cell-penetrating peptides that do not require a GLP-1R (Elahi et al., 2014). GLP-1(32–36) amide, a novel pentapeptide cleavage product of GLP-1, modulates whole-body glucose metabolism in dogs (Elahi et al., 2014). GLP1-derived nonapeptide GLP1(28–36) amide preserves pancreatic β cells from glucolipotoxicity (Liu et al., 2012) and activates PKA and Wnt signaling [reviewed in (Jin and Weng, 2016)]. The beneficial effects of GLP-1 fragments were reported to include kidney protective effects in db/db mice with diabetes (Moellmann et al., 2018). Whether such GLP-1 derived fragments are relevant for the GLP-1-induced liver autophagy induction is not known and required further investigation.

A series of experiments provided evidence that a GLP-1 agonist ameliorated hepatic steatosis and metabolic defects. Such antisteatotic and metabolic effects of GLP-1 on the liver could involve AMPK activation and suppression of the mTOR pathway. Liraglutide has been shown to halt the progression of steatosis and is associated with the induction of autophagy via activation of AMPK and suppression of mTOR pathways (He et al., 2016). By activating both macro- and chaperone-mediated autophagy, GLP-1 could protect hepatocytes from fatty acid-related apoptosis by suppressing a dysfunctional ER stress response. GLP-1 therapies have been shown to relieve the burden on the ER, reduce ER stress, and decrease subsequent hepatocyte apoptosis (Sharma et al., 2011).

The alternative explanation of autophagy induction by GLP-1 could be associated with suppression of oxidative stress. GLP-1 agonists have been shown to reduce oxidative stress in diverse preclinical studies. When the endogenous antioxidant system cannot remove free radicals appropriately, oxidative stress, the accumulation of such free radicals, accelerates a variety of disease conditions, such as diabetes and its complications, cancer, and neuronal disorders. Cellulardefense systems for combatting reactive oxygen species (ROS) rely on the presence of antioxidants that scavenge ROS or induce genes involved in cytoprotection to neutralize ROS (Kaspar et al., 2009; Ma, 2013). The nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor is a master regulator of redox balance and is responsible for the transcription of various antioxidant and detoxification genes by binding to antioxidant response elements (AREs) (Kaspar et al., 2009; Ma, 2013). GLP-1 agonists have been shown to induce Nrf2 in β cells (Oh and Jun, 2017).

When cells are exposed to oxidative stress, SQSTM1, known as the ubiquitin-binding protein p62 and an autophagosome cargo protein, is phosphorylated at Ser349. Phosphorylated form of SQSTM1 physically interacted with KEAP1, an adaptor of the ubiquitin ligase complex for Nrf2, with high affinity (Ueno and Komatsu, 2017). The interaction between SQSTM1 and KEAP1 results in the suppression of KEAP1-driven ubiquitination of Nrf2; phosphorylated SQSTM1 and KEAP1 complexes are selectively degraded by autophagy (Ueno and Komatsu, 2017). Thereafter, Nrf2 is stabilized, translocates into the nucleus, and induces the expression of various essential cytoprotective genes, such as NAD(P)H dehydrogenase quinone 1, glutathione
S-transferase, glutamate-cysteine ligase catalytic subunit and heme oxygenase 1 (Jain et al., 2010; Komatsu et al., 2010; Lau et al., 2010; Taguchi et al., 2012; Ichimura et al., 2013). Sestrin 2, also known as an intracellular leucine sensor that negatively regulates mTORC1 signaling, binds with the SQSTM1 and KEAP1 complexes and functions as a scaffold protein for the SQSTM1-mediated autophagy of KEAP1 (Bae et al., 2013). Sestrin 2 is also induced under conditions of stress (Yang et al., 2014); Nrf2 activation might be regulated by selective autophagy under metabolic stress. Therefore, GLP-1-induced Nrf2 activation could be relevant to GLP-1-induced autophagy, but further study is needed. The association between GLP-1 and sestrin 2 has yet to be confirmed.

DPP-4 INHIBITORS-INDUCED AUTOPHAGY

DPP-4, a member of the serine peptidase/prolyl oligopeptidase gene family, was first found as a T cell differentiation antigen (CD26) and also as cell surface aminopeptidase. DPP-4 displays numerous biological functions, such as protease activity, interaction with adenosine deaminase and the extracellular matrix proteins, co-receptor activity mediating viral entry, and regulation of intracellular signals (Kameoka et al., 1993; Kahne et al., 1999; Lambeir et al., 2003; Lopez-Otin and Matrisian, 2007; Lu et al., 2013). Furthermore, the complexities of the biological functions of DPP-4 are indeed multiplying with diverse bioactive substrates of DPP-4, thus emphasizing the elegant role of DPP-4 in the biochemical tuning of multiple cell type and tissues. DPP-4 inhibitors exhibited multiple organ protective potential (Kroller-Schon et al., 2012; Itou et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018) and also influenced cancer biology (Abrahami et al., 2013; Kanasaki, 2016; Zhuge et al., 2016; Avogaro and Fadini, 2018).

Some preclinical studies have shown a potential link between DPP-4 inhibition and autophagy induction. In leptin-deficient ob/ob mice, sitagliptin at 50 mg/kg daily for 4 weeks ameliorated weight gain, metabolic disorders, and steatosis in the liver as well as insulin sensitivity. In this study, sitagliptin increased AMPK phosphorylation and decreased mTOR phosphorylation associated with the restoration of ATG5 and Beclin 1 messenger RNA expression that was suppressed in ob/ob mice. In addition, the relative level of LC3-II/LC3-I was significantly diminished in ob/ob mice and was restored to the basal level by sitagliptin (Zheng et al., 2018). Another report showed that autophagic responses were significantly diminished in OLETF rats after experimental myocardioc infarction associated with a deficiency in AMPK/ULK-1 activation, Akt/mTOR/S6 signaling, and increased Beclin-1-Bcl-2 interaction, which are key molecular events for suppressing autophagy. Intervention with the DPP-4 inhibitor vildagliptin inhibited the Beclin-1-Bcl-2 interaction and enhanced both LC3-II protein and autophagosomes in the non-infarcted region in OLETF rats without normalization of either AMPK/ULK-1 or mTOR/S6 signaling. Such effects of vildagliptin on heart autophagy are associated with an 80% survival rate in OLETF rats; chloroquine, an autophagy inhibitor, diminished these beneficial effects of vildagliptin (Murase et al., 2015).

Reports have indicated that DPP-4 inhibitors could be associated with the induction of autophagy; however, the underlying mechanisms by which DPP-4 inhibition is related to autophagy induction are not absolutely clear. It may involve an increase in levels of GLP-1 by DPP-4 inhibitor treatment. DPP-4 inhibitor enhanced insulin secretion and induction of autophagy signals in the islets of high-fat-fed mice; such effects of DPP-4 inhibition on autophagy signaling were completely abolished by GLP-1R antagonist exendin 9-39 coadministration (Liu et al., 2016).

DPP-4 AND EXTRACELLULAR MATRIX INTERACTION: RELEVANCE TO AUTOPHAGY SUPPRESSION

Other than GLP-1 induction, the pleiotropic effects of a DPP-4 inhibitor may be relevant to the mechanisms of autophagy induction by DPP-4 inhibition. The interaction with the extracellular matrix is an important determinant of cell fate. Integrins are glycoproteins that play vital roles in cell–cell or cell–matrix interactions through αβ heterodimers. Eighteen α and eight β subunits of integrins are known, and each of them displays diverse ligand binding and signaling properties (Pozzi and Zent, 2011). Integrin subunits consist of an extracellular domain that is important for their ligand binding properties and contains a transmembrane domain and a short cytoplasmic tail, which could interact with diverse cytosolic and transmembrane proteins by consisting a focal adhesion complex (with the exception of β4) (Pozzi and Zent, 2003). Integrins display physical interaction with several extracellular matrix (ECM) glycoproteins (such as collagens, fibronectins, and laminins) and cellular receptors (Plow et al., 2000; Hynes, 2002). Integrins are essential molecules in actin cytoskeleton remodeling and in regulating cell signals that regulate biological and cellular functions (Park et al., 2015). Integrins display intracellular signaling through ligand binding (“outside-in” signaling) (Ratnikov et al., 2005). Alternatively, integrins can alter their high- to low-affinity conformations, facilitating specific ligand binding (“inside-out” signaling) (Luo et al., 2007). The activation status of integrin relies on the cell type. In most cells that adhere to the basement membrane, integrins are activated; in contrast, integrins are inactive in circulating platelets or leukocytes until they are induced by platelet aggregation or stimulated by an inflammatory response. Integrins contain neither a catalytic site nor kinase activity but play a role as a bridge between the ECM and actin cytoskeleton. Such interaction between the ECM and the actin cytoskeleton through integrins allows integrins to maintain cytoskeletal organization, cell motility and intracellular-signaling pathways such as cell survival, cell shape, cell proliferation, and angiogenesis (Arnaout et al., 2007; Luo et al., 2007).

Indeed, DPP-4 is the molecule that interacts with the key integrin, integrin β1 (Figure 3), which can form a heterodimer with at least 11 α-subunits. Integrin β1 has the biological function
FIGURE 3 DPP-4 may target integrin β1-mediated suppression of autophagy. On the cell membrane, DPP-4 displays an interaction with integrin β1. Integrin β1 is important for focal adhesion complexes. These integrin β1-mediated cell adhesion complexes potentially inhibit both anoikis and autophagy. Indeed, autophagy is an important biological mechanism for protecting cells from anoikis as well. Autophagy also targets and inhibits focal adhesion complexes.

of a “hub integrin” and acts as a receptor for specific ECM components, revealed in kidney epithelial cells (Glynne et al., 2001) or in T cell lymphoma (Elias et al., 2014). The loss of membrane-bound DPP-4 has been associated with suppression of the phosphorylation of integrin β1 S785, which plays a key role in the cellular adhesion of integrin β1 to the ECM (Sato et al., 2005). We have shown that the DPP-4 inhibitor linagliptin suppressed the interaction between DPP-4 and integrin β1, subsequently inhibiting the endothelial to mesenchymal transition program (Shi et al., 2015; Kanasaki, 2016), the fibrogenic programs associated with the inhibition of autophagy (Singh et al., 2015). Interestingly, in addition to the biological importance of integrin β1 on the suppression of autophagy, the autophagy pathway targets integrin β1 during nutrient starvation (Vlahakis and Debnath, 2017). Autophagy degrades focal adhesion proteins and promotes turnover of those molecules (Vlahakis and Debnath, 2017). Additionally, integrin-mediated cell adhesion to the ECM has been shown to protect cells from anoikis, the apoptosis induced by the lack of correct cell/ECM attachment. Once integrin-mediated interaction with the ECM is lost, cells induce autophagy for survival (Figure 3). Autophagy induction has been shown to promote the survival of epithelial cells and adjustments in the absence of cell–matrix contact, resulting in the anoikis resistance (Yang et al., 2013; Chen et al., 2017; Talukdar et al., 2018) (Figure 3). After autophagy was inhibited by either RNA interference or harboring of oncogenes, cells lost their ability to combat anoikis (Figure 3).

PERSPECTIVE: BARIATRIC SURGERY AND AUTOPHAGY INDUCTION

Bariatric surgery, including Roux-en-Y (RYGB), gastric banding, sleeve gastrectomy (SG), and biliopancreatic diversion (BPD), has been a beneficial intervention in the treatment of obesity for reduction in body weight and is associated with the amelioration of liver steatosis and metabolic defects. However, the detailed molecular mechanisms of the beneficial metabolic effects of bariatric surgery have not been completely established.

Some reports indicate that amelioration of metabolic profiling by gastrectomy was associated with autophagy induction (Soussi et al., 2016). Several possible explanations were made for this interesting phenomenon. After bariatric surgery, significant alterations in anatomical structure induced changes in the integrated responses during eating, including cephalic phase, chewing and tasting, gastric phase, intestinal phase and gut peptides, absorptive phase, glucose metabolism, liver and bile acid phase, and large intestine and microbiota phase [summarized in ref (Quercia et al., 2014)]. The molecules described in this review could be also notable for their significance in autophagy induction by bariatric surgery (Figure 4).

Glucagon

In the stomach, gastric emptying is regulated by gastric content and neural and hormonal influences and is altered after bariatric surgery as described earlier. Accelerated gastric emptying time for liquids but slower gastric emptying time for solids have been reported after RYGB (Horowitz et al., 1982). Kotler et al. (1985) reported faster intestinal transit time and increased enteroglucagon levels in patients with greater weight loss compared to weight-stable patients. The term “enteroglucagon” in this report did not necessarily include “glucagon” because of cross reaction with several glucagon sequence-containing polypeptides at the time of this report. The presence of extrapancreatic glucagon secretion in humans has been the focus of intense discussion for years, and even though evidence was conflicting, some investigators reported that glucagon responses after total pancreatectomy were present in animals (Sutherland and De Duve, 1948; Matsuyama and Foa, 1974; Vranic et al., 1974; Muller et al., 1978; Doi et al., 1979; Gotoh et al., 1989) and humans (Unger et al., 1966;
Barnes and Bloom, 1976; Villanueva et al., 1976; Boden et al., 1980; Karesen et al., 1980; Sudo et al., 1980; Dammann et al., 1981; Holst et al., 1983; Yasui, 1983; Polonsky et al., 1984; Bajorunas et al., 1986a,b; Ohtsuka et al., 1986; Tanjoh et al., 2003). The most challenging point was that until recently, analytical methods for glucagon have not been sufficiently sensitive or specific to justify decisive statements about the absence or presence of extrapancreatic fully processed 29–amino acid glucagon (Tanjoh et al., 2003). Recently, sandwich enzyme-linked immunosorbent assays (ELISA) utilizing a combination of C- and N-terminal antiglucagon antibodies have been emerged. Such ELISA system theoretically could eliminate cross-reactivity with truncated or elongated forms of glucagon containing polypeptides (Wewer Albrechtsen et al., 2014). Lund et al. (2016) studied patients who underwent total pancreatectomy and analyzed plasma glucagon levels. As expected, the gastrointestinal anatomy was remarkably changed, including the removal of the pyloric sphincter and duodenum after total pancreatectomy. Therefore, following the ingestion of a meal, nutrients are rerouted and delivered directly from the stomach to the jejunum in a manner similar to bariatric surgery as previously described. The unique point of the study by Lund et al. (2016) is that they utilized not only novel sandwich enzyme-linked immunosorbent assays of plasma glucagon but also mass spectrometry-based proteomics to confirm 29-amino acid circulatory glucagon levels in patients without a pancreas. Basal glucagon levels in these patients exhibited a lower trend, and glucose challenge of the gastrointestinal tract exerted significant hyperglucagonemia in these patients. Lund et al. (2016) also confirm that the intravenous glucose infusion attenuated plasma glucagon levels, and directs focus on the gastrointestinal tract. Unfortunately, there is no direct evidence indicated the hyperglucagonemia after bariatric surgery yet, but higher glucagon release within the first 2 h and higher trend of peak level of glucagon in post RYGB patients when compared to SG or neither operation group has been recently reported (Svane et al., 2019). These findings suggest that alteration in glucagon secretion or possibly hyperglucagonemia could be induced by bariatric surgery and be relevant in systemic physiological alterations, including autophagy (Figure 4). Subsequently such induction of autophagy could influence on the health in individuals with obesity but also in lean and in malnourished patients after gastrectomy. Further research would be required in this field.

**GLP-1**

The potential contribution of GLP-1 to the pathobiological alteration that occurs after bariatric surgery was seen in adverse outcomes of bariatric surgery. Late dumping syndrome, a well-known hypoglycemic event, occurs 2–3 h after a meal, after gastric surgery, and as a complication after surgery for obesity as well. The underlying cause of late dumping syndrome is not completely understood, but in general, it is hypothesized that postoperative elevation of incretin hormone, especially GLP-1 levels, leads to pancreatic β-cell hypertrophy (Figure 4). Such β-cell hypertrophy stimulates insulin secretion and hypoglycemic symptoms. These theories are supported by the observation that hyperinsulinemic hypoglycemia most frequently occurred...
in patients who underwent resection of parts of the stomach, in which the gastrojejunostomy bypasses the pylorus. Therefore, induced levels of GLP-1 during an oral glucose or meal test have been consistently reported after RYGB (Yi et al., 2008), BPD (Jin and Weng, 2016), and SG (Moellmann et al., 2018) (Figure 4). Even though none of these theories have been mechanistically proven during a hypoglycemic event, an increase in GLP-1 could be associated with hepatic autophagy. He et al. (2015) reported that in a study of rats with obesity and diabetes, RYGB led to significant induction of autophagy in the liver, restored autophagy levels in the liver and was associated with reducing the level of hepatic lipids. Increased autophagy in the liver after RYGB was well correlated with plasma GLP-1 levels (He et al., 2015). Therefore, induction of GLP-1 after bariatric surgery would also lead to significant stimulation of autophagy (Figure 4).

CONCLUSION

In this review, we focused on glucagon/GLP-1 and associated drugs in the physiology of autophagy. We propose that changes in the gastrointestinal tract that induces food to bypass the intestine would be relevant to the induction of autophagy via secretion of GLP-1 and/or glucagon.

AUTHOR CONTRIBUTIONS

KK concept, design, and major contribution to writing the manuscript. EK made figures and discussion. DK intellectual input in the projects.

FUNDING

This study was essentially supported by a grant from the Japan Diabetes Foundation (2016). This work was partially supported by grants from the Japan Society for the Promotion of Science for KK (23790381 and 23790381) and DK (25282028 and 25670414). This work was partially supported by a Grant for Promoted Research awarded to KK (S2017-1) from Kanazawa Medical University. Boehringer Ingelheim, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical contributed to establishing the Division of Anticipatory Molecular Food Science and Technology.

REFERENCES

Abrahami, D., Yin, H., Yu, O. H. Y., Pollak, M. N., and Azoulay, L. (2018). Incrined-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. *Epidemiology* 29, 246–253. doi: 10.1097/EDE.0000000000000793

Amherdt, M., Harris, V., Renold, A. E., Orci, L., and Unger, R. H. (1974). Hepatic autophagy in uncontrolled experimental diabetes and its relationships to insulin and glucagon. *J. Clin. Invest.* 54, 188–193. doi: 10.1172/jci107742

Arden, C. (2018). A role for glucagon-like peptide-1 in the regulation of beta-cell autophagy. *Peptides* 100, 85–93. doi: 10.1016/j.peptides.2017.12.002

Arnaout, M. A., Goodman, S. L., and Xiong, J. P. (2007). Structure and mechanics of integrin-based cell adhesion. *Curr. Opin. Cell Biol.* 19, 495–507. doi: 10.1016/j.cceb.2007.08.002

Arvila, A. U., and Trump, B. F. (1968). Studies on cellular autophagocytosis. The formation of autophagic vacuoles in the liver after glucagon administration. *Am. J. Pathol.* 53, 687–733.

Ashford, T. P., and Porter, K. R. (1962). Cytoplasmic components in hepatic cell lysosomes. *J. Cell Biol.* 12, 198–202. doi: 10.1083/jcb.12.1.198

Aviv, V., Meivar-Levy, I., Rachmut, I. H., Rubinek, T., Mor, E., and Ferber, S. (2009). Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. *J. Biol. Chem.* 284, 33509–33520. doi: 10.1074/jbc.M109.017608

Avogaro, A., and Fadini, G. P. (2018). The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. *Br. J. Clin. Pharmacol.* 84, 1686–1695. doi: 10.1111/bcp.13611

Barnes, A. J., and Bloom, S. R. (1976). Pancreatectomised man: a model for diabetes mellitus? *Science and Technology.* 1, 219–221. doi: 10.1016/s0140-6736(76)91339-8

Becker, F. F., and Cornell, C. C. Jr. (1971). Phlorizin induced autophagyosis during hepatic glycogenolysis. *Exp. Mol. Pathol.* 14, 103–109. doi: 10.1016/0014-4800(71)90056-6

Bodin, G., Master, R. W., Rernvani, L., Palmer, J. P., Lobe, T. E., and Owen, O. E. (1980). Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. *J. Clin. Invest.* 65, 706–716. doi: 10.1172/jci109717

Brekke, I. B., Danielsen, H., and Reith, A. (1983). Normalization of hepatic lysosomal autophagy in streptozotocin diabetic rats after pancreatic transplantation. *Virochows Arch. B Cell Pathol. Incl. Mol. Pathol.* 43, 189–197. doi: 10.1017/fbo2932956

Bryant, M. G., and Bloom, S. R. (1979). Distribution of the gut hormones in the primate intestinal tract. *Gut* 20, 653–659. doi: 10.1136/gut.20.8.653

Bullock, B. P., Heller, R. S., and Habener, J. F. (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. *Endocrinology* 137, 2968–2978. doi: 10.1210/en.137.7.2968

Cantini, G., Mannucci, E., and Luconi, M. (2016). Perspectives in GLP-1 research: new targets. New receptors. *Trends Endocrinol. Metab.* 27, 427–438. doi: 10.1016/j.tem.2016.03.017

Chen, J. L., David, J., Cook-Spaeth, D., Casey, S., Cohen, D., Selvendiran, K., et al. (2017). Autophagy induction results in enhanced anokia resistance in models of peritoneal disease. *Mol. Cancer Res.* 15, 26–34. doi: 10.1158/1541-7786.MCR-16-0200-T

Chiang, Y. T., Ip, W., and Jin, T. (2012). The role of the Wnt signaling pathway in incretin hormone production and function. *Front. Physiol.* 3:273. doi: 10.3389/fphys.2012.00273

Codogno, P., Mehrpour, M., and Przkas-Cezanne, T. (2011). Canonical and non-canonical autophagy: variations on a common theme of self-eating? *Nat. Rev. Mol. Cell Biol.* 13, 7–12. doi: 10.1038/nrm3249

D’Alessio, D., Vahl, T., and Prigeon, R. (2004). Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. *Horm. Metab. Res.* 36, 837–841. doi: 10.1055/s-2004-826172

Dammann, H. G., Besterman, H. S., Bloom, S. R., and Schreiber, H. W. (1981). Formation of autophagic vacuoles in the liver after glucagon administration. *Cell Biol.* 53, 687–733.

De Duve, C., Pressman, B. C., Gianetto, R., Wattiaux, R., and Appelmans, F. (1955). Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. *Biochem. J.* 60, 604–617. doi: 10.1042/bj0600604
Deter, R. L. (1971). Quantitative characterization of dense body, autophagic vacuole, and acid phosphatase-bearing particle populations during the early phases of glucagon-induced autophagy in rat liver. J. Cell Biol. 48, 473–489. doi: 10.1083/jcb.48.3.473

Deter, R. L., and De Duve, C. (1967). Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. J. Cell Biol. 33, 437–449. doi: 10.1083/jcb.33.3.437

Doi, K., Prentki, M., Yip, C., Muller, W. A., Jeannreaud, B., and Vrano, M. (1979). Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon. J. Clin. Invest. 63, 525–531. doi: 10.1172/jci109331

Elahi, D., Angelis, F. S., Vakilpour, A., Carlson, O. D., Tomas, E., Egan, J. M., et al. (2014). GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides 59, 20–24. doi: 10.1016/j.peptides.2014.06.004

Elias, B. C., Mathew, S., Srichai, M. B., Palamutman, R., Bulus, N., Merrough, G., et al. (2014). The integrin beta1 subunit regulates paracellular permeability of kidney proximal tubule cells. J. Biol. Chem. 289, 8532–8544. doi: 10.1074/jbc.M113.256509

Enz, N., Vliegen, G., De Meester, I., and Jungraithmayr, W. (2019). CD26/DPP4 - a potential biomarker and target for cancer therapy. Pharmacol. Ther. [Epub ahead of print].

Flock, G., Baggio, L. L., Longuet, C., and Drucker, D. J. (2007). Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildaglipitin in mice. Diabetes Metab. Res. Rev. 56, 3006–3013. doi: 10.2337/db07-0697

Glynné, P. A., Picot, J., and Evans, T. J. (2001). Coexpressed nitric oxide synthase in rat liver. The influence of age, nutritional state and adrenal function on the effect of glucagon on lysosomal N-acetyl-beta-D-glucosaminidase. J. Endocrinol. 170, 615–624.

Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., et al. (2010). Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51, 1584–1592. doi: 10.1002/hep.23569

Han, V. K., Hynes, M. A., Jin, C., Towle, A. C., Lauder, J. M., and Lund, P. K. (1986). Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br. J. Surg. 73, 237–242. doi: 10.1002/bjs.2800730226

He, Q., Sha, S., Sun, L., Zhang, J., and Dong, M. (2016). GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochim. Biophys. Acta 222, 593–605. doi: 10.1016/0304-4165(70)90185-6

Hollande, C., Boussier, J., Ziai, J., Nozawa, T., Bondet, V., Phung, W., et al. (2019). Inhibition of the dipeptidyl peptidase DFP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat. Immunol. 20, 97–107. doi: 10.1038/s41590-019-0321-5

Holst, J. J., Pedersen, J. H., Baldissera, F., and Stadil, F. (1983). Circulating glucagon during total pancreatectomy in man. Diabetologia 25, 396–399. doi: 10.1007/bf00282517

Horowitz, M., Cook, D. J., Collins, P. J., Harding, P. E., Hooper, M. J., Walsh, J. F., et al. (1982). Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br. J. Surg. 69, 655–657. doi: 10.1002/bjs.1800691108

Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687.
Oh, Y. S., and Jun, H. S. (2017). Effects of glucagon-like peptide-1 on oxidative stress and toxicity. *Annu. Rev. Pharmacol. Toxicol.* 53, 401–426. doi: 10.1146/annurev-pharmtox-011112-140320

Maiztegui, B., Boggio, V., Roman, C. L., Flores, L. E., Zotto, H. D., Ropolo, A., et al. (2017). VPMP1-related autophagy induced by a fructose-rich diet in beta-cells: its prevention by incretins. *Clin. Sci.* 131, 673–687. doi: 10.1042/CS20170010

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M., et al. (2018). Effects of drug classes on cardiovascular disease outcomes in patients with type 2 diabetes and high cardiovascular and renal risk: the carmela randomized clinical trial. *JAMA* 321, 69–79. doi: 10.1001/jama.2018.16269

Rowlands, J., Heng, J., Newsholme, P., and Carlessi, R. (2018). Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. *Front. Endocrinol.* 9:672. doi: 10.3389/fendo.2018.00672

Sato, T., Yamochi, T., Yamochi, T., Aytac, U., Ohnuma, K., McKee, K. S., et al. (2015). CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin αβ1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. *Cancer Res.* 65, 6950–6956. doi: 10.1158/0008-5472.can-05-0647

Sharma, S., Melis, E. J., Fu, P. P., Saxena, N. K., and Anania, F. A. (2011). GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. *PLOS One* 6, e25269. doi: 10.1371/journal.pone.0025269

Shelburne, J. D., Arstila, A. U., and Trump, B. F. (1973). Studies on cellular anatomical delineation of sources. *J. Biol. Chem.* 248, 2140–2149. doi: 10.1016/b02773909

Singh, K. K., Lovren, F., Pan, Y., Quan, A., Ramadan, A., Matkar, P. N., et al. (2015). Inhibition of DPP-4 reduces acute mortality after myocardial infarction with effective suppression of glucose production in isolated mouse hepatocytes. *Diabetes Metab. Res. Rev.* 60, 658–662. doi: 10.1007/s00722-015-0016-8

Soussi, H., Clement, K., and Daguil, I. (2016). Adipose tissue autophagy status in obesity: expression and flux–two faces of the picture. *Autophagy* 12, 588–589. doi: 10.1002/aji.21052

Sudo, T., Suzuki, T., and Tobe, T. (1980). Changes in plasma glucagon after total pancreatectomy in man. *Gastroenterology* 79, 464–468. doi: 10.1010/bf02773909

Sutherland, E. W., and De Duve, C. (1948). Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. *J. Biol. Chem.* 175, 663–674.


doi: 10.1007/s00722-015-0016-8

Suvanto, A., Karlamis, S., Poussa, J., Mäkinen, M., Koskenvuo, M., Laine, M., et al. (2013). Glucagon-like peptide-1 improves the autophagic flux of islets in T2D. *Diabetes Metab. Res. Rev.* 29, 663–670. doi: 10.1002/dmrr.1147

Tabuchi, K., Fukushima, N., Komatsu, M., Iishi, T., Unno, M., Akaite, T., et al. (2012). Keap1 degradation by autophagy for the maintenance of redox homeostasis. *Front. Immunol.* 3, 101. doi: 10.3389/fgene.2012.00101

Takahashi, K., Zhu, X., Li, Y., and Gao, F. (2014). Metformin decreases the expression of PAC1R and GLUT-1 in pancreatic beta-cells. *Cell. Physiol. Biochem.* 34, 875–883. doi: 10.1159/000362564

Takagi, Y., Hirano, T., and Maruyama, T. (2007). Effects of metformin on glucose-stimulated insulin secretion and pancreatic messenger RNA expression in subjects with impaired glucose tolerance. *Diabetes Obes. Metab.* 9, 379–389. doi: 10.1111/j.1463-1326.2006.00783.x

Takahashi, K., Zhu, X., Li, Y., and Gao, F. (2014). Metformin decreases the expression of PAC1R and GLUT-1 in pancreatic beta-cells. *Cell. Physiol. Biochem.* 34, 875–883. doi: 10.1159/000362564

Takagishi, K., Yoshida, K., Nishizawa, K., Chishima, H., and Ikeda, Y. (2008). Treatment with metformin reduces oxidative stress in activated macrophages and ameliorates hepatic fibrosis in streptozotocin-induced diabetic rats. *Diabetes Metab. J.* 32, 507–515. doi: 10.15332/dmj2008028

Takamura, K., Komatsu, M., Iishi, T., Unno, M., Akaite, T., et al. (2012). Keap1 degradation by autophagy for the maintenance of redox homeostasis. *Front. Immunol.* 3, 101. doi: 10.3389/fgene.2012.00101

Takahashi, K., Zhu, X., Li, Y., and Gao, F. (2014). Metformin decreases the expression of PAC1R and GLUT-1 in pancreatic beta-cells. *Cell. Physiol. Biochem.* 34, 875–883. doi: 10.1159/000362564

Takagishi, K., Yoshida, K., Nishizawa, K., Chishima, H., and Ikeda, Y. (2008). Treatment with metformin reduces oxidative stress in activated macrophages and ameliorates hepatic fibrosis in streptozotocin-induced diabetic rats. *Diabetes Metab. J.* 32, 507–515. doi: 10.15332/dmj2008028

Takamura, K., Komatsu, M., Iishi, T., Unno, M., Akaite, T., et al. (2012). Keap1 degradation by autophagy for the maintenance of redox homeostasis. *Front. Immunol.* 3, 101. doi: 10.3389/fgene.2012.00101

Takahashi, K., Zhu, X., Li, Y., and Gao, F. (2014). Metformin decreases the expression of PAC1R and GLUT-1 in pancreatic beta-cells. *Cell. Physiol. Biochem.* 34, 875–883. doi: 10.1159/000362564

Takagishi, K., Yoshida, K., Nishizawa, K., Chishima, H., and Ikeda, Y. (2008). Treatment with metformin reduces oxidative stress in activated macrophages and ameliorates hepatic fibrosis in streptozotocin-induced diabetic rats. *Diabetes Metab. J.* 32, 507–515. doi: 10.15332/dmj2008028

Takahashi, K., Zhu, X., Li, Y., and Gao, F. (2014). Metformin decreases the expression of PAC1R and GLUT-1 in pancreatic beta-cells. *Cell. Physiol. Biochem.* 34, 875–883. doi: 10.1159/000362564

Takagishi, K., Yoshida, K., Nishizawa, K., Chishima, H., and Ikeda, Y. (2008). Treatment with metformin reduces oxidative stress in activated macrophages and ameliorates hepatic fibrosis in streptozotocin-induced diabetic rats. *Diabetes Metab. J.* 32, 507–515. doi: 10.15332/dmj2008028
Ueno, T., and Komatsu, M. (2017). Autophagy in the liver: functions in health and disease. *Nat. Rev. Gastroenterol. Hepatol.* 14, 170–184. doi: 10.1038/nrgastro.2016.185

Ungr, R. H., Ketterer, H., and Eisentraut, A. M. (1966). Distribution of immunoassayable glucagon in gastrointestinal tissues. *Metabolism* 15, 865–867. doi: 10.1016/0026-0495(66)90156-9

Villanueva, M. L., Hedo, J. A., and Marco, J. (1976). Plasma glucagon immunoreactivity in a totally pancreatectomized patient. *Diabetologia* 12, 613–616. doi: 10.1007/bf01220639

Vlahakis, A., and Debnath, J. (2017). The interconnections between autophagy and integrin-mediated cell adhesion. *J. Mol. Biol.* 429, 515–530. doi: 10.1016/j.jmb.2016.11.027

Vrang, N., Hansen, M., Larsen, P. J., and Tang-Christensen, M. (2007). Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei. *Brain Res.* 1149, 118–126. doi: 10.1016/j.brainres.2007.02.043

Vranic, M., Pek, S., and Kawamori, R. (1974). Increased 'glucagon immunoreactivity' in plasma of totally depancreatized dogs. *Diabetes Metab. Res. Rev.* 23, 905–912. doi: 10.2337/db16.22.905

Wewer Albrechtsen, N. J., Hartmann, B., Veedfald, S., Windelov, J. A., Plamboeck, A., Bojsen-Moller, K. N., et al. (2014). Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? *Diabetologia* 57, 1919–1926. doi: 10.1007/s00125-014-3283-z

Ye, H., Adane, B., Khan, N., Alexeev, E., Nusbacher, N., Minhajuddin, M., et al. (2018). Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. *Cancer Cell* 34, 659–673.e6. doi: 10.1016/j.ccell.2018.08.016

Yi, F., Sun, J., Lim, G. E., Fantus, I. G., Brubaker, P. L., and Jin, T. (2008). Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. *Endocrinology* 149, 2341–2351. doi: 10.1210/en.2007-1142

Zheng, W., Zhou, J., Song, S., Kong, W., Xia, W., Chen, L., et al. (2018). Dipeptidylpeptidase 4 inhibitor sitagliptin ameliorates hepatic insulin resistance by modulating inflammation and autophagy in ob/ob mice. *Int. J. Endocrinol.* 2018:8309723. doi: 10.1155/2018/8309723

Zhu, F., Ni, Y., Nagashima, M., Nagata, N., Xu, L., Mukaida, N., et al. (2016). DPP-4 inhibition by linaglaptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. *Diabetes Metab. Res. Rev.* 65, 2966–2979. doi: 10.2337/db16-0317

Zummo, F. P., Cullen, K. S., Honkanen-Scott, M., Shaw, J. A. M., Lovat, P. E., and Arden, C. (2017). Glucagon-like peptide 1 protects pancreatic beta-cells from death by increasing autophagic flux and restoring lysosomal function. *Diabetes Metab. Res. Rev.* 66, 1272–1285. doi: 10.2337/db16-1009

Conflict of Interest Statement: KK is under a consultancy agreement with Boehringer Ingelheim.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kanasaki, Kawakita and Koya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.